
    
      Study Further Study Details:

      Primary outcome: pill-taking compliance (total doses taken versus total doses prescribed)

      Expected Total Enrollment: 400 subjects at 56 study sites in the U.S.

      Study Start: October 2005

      This is a 5-month double-blind treatment study of male and female subjects with stable
      mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of
      heart failure.

      Eligibility:

      Must be stable on treatment with Coreg IR at a standard dose: 6.25, 12.5, 25 mg twice a day.
    
  